Scientific Programme

22 July 202123 July 202124 July 2021

13.30 – 14.00	Welcome and Rising Star Session
14.00 – 14.20	SO1. An update on treatment of anxiety disorders Borwin Bandelow (Germany)
14.20 – 14.30	Discussion
14.30 – 14.50	SO2. Psychobiotics for stress Disorders Ted Dinan (UK)
14.50 – 15.00	Discussion
15.00 – 15.20	SO3. Functional outcome of bipolar disorders Allan Young (UK)
15.20 – 15.30	Discussion
15.30 – 15.50	SO4. Mental health effects of the COVID-19 pandemic Carmen Moreno (Spain)
15.50 – 16.00	Discussion
16.00 – 16.20	SO5. Depression as an episodic condition Philip Goorwood (France)
16.20 – 16.30	Discussion

13.00 – 13.20	SO6. Treatment Resistant Depression: findings from an European study Siegfried Kasper (Austria)
13.20 – 13.30	Discussion
13.30 – 13.50	SO7. Psychedelics in Psychiatry Sidney Kennedy (Canada)
13.50 – 14.00	Discussion
14.00 – 14.30	Supported Symposium
14.30 – 14.40	Discussion
14.40 – 15.00	SO8. Impulsive and compulsive disorders Naomi Fineberg (UK)
15.00 – 15.10	Discussion
15.10 – 15.30	S9. Personalised Psychiatry. Are we there yet? Chiara Fabbri (Italy)
15.30 – 15.40	Discussion
15.40 – 16.00	S10. Hazards in the treatment of anxiety and depression: findings from the National Clinical Audit of Anxiety and Depression David Baldwin (UK)
16.00 – 16.10	Discussion
16.10 – 16.30	S11. Are polygenic risk scores useful for treatment choice? Alessandro Serretti (Italy)
16.30 – 16.40	Discussion

09.30 – 09.50	S12. Prevention of suicide Philippe Courtet (France)
09.50 – 10.00	Discussion
10.00 – 10.20	S13. Novel Antipsychotics Eduard Vieta (Spain)
10.20 – 10.30	Discussion
10.30 – 10.50	S14. Depression and substance use disorders: state of the art Marta Torrens Melich (Spain)
10.50 – 11.00	Discussion
11.00 – 11.20	S15. Inflammation in Mood and Anxiety Disorder Bernard Baune (Germany)
11.20 – 11.30	Discussion
11.30 – 11.50	S16. Treatment of schizophrenia: is monotherapy the gold standard? Istvan Bitter (Hungary)
11.50 – 12.00	Discussion
12.00 – 12.30	Closing remarks